Missouri Cannabis Antitrust Cases: Market Manipulation Lawsuits Explained

Executive Summary

Missouri's cannabis industry faces unprecedented antitrust scrutiny as a major multi-state operator confronts its second federal lawsuit alleging anticompetitive conduct and market manipulation. The consumer class action, filed in May 2026, accuses the vertically integrated cannabis company of leveraging its dominant market position to inflate retail prices, restrict competitor access to wholesale supply, and create artificial scarcity in Missouri's adult-use cannabis market. This litigation represents the most significant legal challenge to cannabis industry consolidation since Missouri transitioned to recreational sales in February 2023, with potential implications for pricing structures, licensing frameworks, and merger review standards across state-legal markets. The cases test whether federal antitrust law—including the Sherman Act and Clayton Act—applies with full force to businesses operating in violation of the Controlled Substances Act, a question that has divided federal courts and could reshape competitive dynamics in the $30 billion U.S. cannabis industry.

Why This Matters

These antitrust cases will determine whether cannabis consumers have legal recourse against monopolistic pricing and whether federal courts will enforce competitive standards in state-legal markets. The stakes extend far beyond Missouri's borders. As of May 2026, 24 states have legalized adult-use cannabis, with combined annual sales exceeding $30 billion. Vertical integration—where single companies control cultivation, processing, distribution, and retail—has become the dominant business model, with the top five multi-state operators controlling approximately 35% of national legal sales. Missouri's market exemplifies this consolidation: the state issued only 282 dispensary licenses and 60 cultivation licenses for a population of 6.2 million, creating natural supply constraints that critics argue enable anticompetitive behavior. For consumers, the litigation addresses bread-and-butter pocketbook issues. Missouri's average retail cannabis price increased 23% between February 2023 and April 2026, according to state Division of Cannabis Regulation data, even as wholesale cultivation costs declined 15% over the same period. The plaintiff class alleges this price divergence reflects market manipulation rather than legitimate supply-demand dynamics. If successful, the lawsuit could force structural changes to vertical integration models and potentially trigger refunds to affected consumers. For operators, the cases present existential risks. Federal antitrust remedies can include forced divestitures, behavioral restrictions on pricing and supply agreements, and treble damages—three times actual harm—under 15 U.S.C. § 15. A major judgment could destabilize acquisition strategies that have driven cannabis industry consolidation since 2018, when Canada's legalization triggered a wave of institutional capital into U.S. operators. Investment banks have already flagged Missouri antitrust exposure in at least six MSO credit analyses since March 2026. For regulators, the litigation exposes tensions between state licensing frameworks designed to limit competition and federal antitrust principles favoring open markets. Missouri's constitutional amendment legalizing cannabis, approved by voters in November 2022, capped licenses and prioritized existing medical operators for adult-use conversion—policy choices that created the concentrated market structure now under legal attack. The outcome may force states to reconsider whether artificial scarcity licensing serves legitimate regulatory goals or simply entrenches incumbent advantages.

Background and History

Missouri's path to cannabis legalization created market conditions ripe for antitrust scrutiny through deliberate license caps and vertical integration incentives.

Medical Cannabis Foundation (2018-2022)

Missouri voters approved Amendment 2 in November 2018, establishing a medical cannabis program that launched in October 2020. The Missouri Department of Health and Senior Services issued 192 dispensary licenses, 60 cultivation licenses, and 86 manufacturing licenses through a competitive scoring process. The program generated $103 million in sales during its first full year of operation in 2021, growing to $265 million in 2022 as patient counts reached 140,000. Critically, Missouri's medical framework permitted vertical integration from inception. Single entities could hold cultivation, manufacturing, and up to five dispensary licenses, enabling companies to control product from seed to sale. By December 2022, the top three vertically integrated operators controlled 41% of dispensary locations and an estimated 55% of cultivation capacity, according to industry publication MJBizDaily. This concentration occurred despite state regulators' stated goal of promoting "diversity of ownership" in licensing rules.

Adult-Use Legalization (November 2022)

On November 8, 2022, Missouri voters approved Amendment 3 with 53.1% support, legalizing adult-use cannabis for individuals 21 and older. The constitutional amendment took effect December 8, 2022, making Missouri the 21st state to legalize recreational cannabis. Crucially, Amendment 3 prioritized existing medical license holders for adult-use conversion, allowing them to begin recreational sales immediately upon regulatory approval without competing against new applicants. The amendment authorized the newly created Division of Cannabis Regulation to issue additional licenses, but capped total dispensaries at 282 statewide—a ratio of approximately one dispensary per 22,000 residents, among the most restrictive in legal states. By comparison, Colorado operates approximately one dispensary per 9,000 residents, and Oregon one per 4,500 residents. Amendment 3 also maintained vertical integration permissions, allowing continued seed-to-sale control.

Market Launch and Consolidation (2023-2024)

Missouri's adult-use market launched February 6, 2023, with 190 dispensaries approved for immediate recreational sales. First-month sales reached $103 million, exceeding projections by 47%. By December 2023, annual adult-use sales totaled $1.1 billion, with medical sales adding $287 million for a combined $1.387 billion market. This rapid growth attracted aggressive consolidation. Between February 2023 and December 2024, the top five MSOs completed 23 acquisitions of Missouri licenses, according to Viridian Capital Advisors. The largest operator expanded from 12 dispensaries in January 2023 to 37 by December 2024, while simultaneously acquiring two of the state's largest cultivation facilities. By year-end 2024, the top three operators controlled 48% of dispensaries and an estimated 62% of cultivation capacity. Wholesale pricing dynamics raised early red flags. Missouri's wholesale cannabis price averaged $1,850 per pound in February 2023, declining to $1,200 per pound by December 2024 as cultivation capacity expanded. Yet retail prices increased over the same period, with the average eighth-ounce retail price rising from $42 in February 2023 to $48 by December 2024—a 14% increase despite falling input costs. Independent retailers reported difficulty securing wholesale supply from vertically integrated cultivators, who allegedly prioritized their own retail outlets.

First Antitrust Lawsuit (March 2026)

On March 12, 2026, a coalition of independent Missouri dispensaries filed a federal antitrust lawsuit in the U.S. District Court for the Western District of Missouri, alleging that the state's largest MSO violated Section 2 of the Sherman Act (15 U.S.C. § 2) through monopolization and attempted monopolization. The complaint alleged the defendant used its dominant cultivation position to engage in vertical foreclosure—restricting wholesale supply to competing retailers while favoring its own dispensaries—and predatory pricing at retail to drive independents out of business. The plaintiff dispensaries cited internal company documents obtained through discovery in an unrelated contract dispute, which allegedly showed deliberate strategies to "consolidate market share through supply control" and "price independents out of premium product categories." The lawsuit sought injunctive relief requiring the defendant to offer wholesale supply on non-discriminatory terms, plus treble damages for lost profits.

Second Lawsuit Filed (May 2026)

On May 18, 2026, a Missouri consumer filed a class action antitrust lawsuit in the same federal district court, alleging the same MSO violated Section 1 of the Sherman Act (15 U.S.C. § 1) through anticompetitive agreements and Section 2 through monopolistic conduct that artificially inflated retail prices. The consumer complaint alleged the defendant's vertical integration and market dominance enabled it to charge supra-competitive prices—prices above what would prevail in a competitive market—resulting in consumer harm estimated at $15 million to $25 million annually. The consumer lawsuit introduced new allegations of horizontal market allocation, claiming the defendant entered into agreements with two smaller competitors to divide geographic territories and avoid price competition in key metropolitan areas. The complaint cited statistical analysis showing retail prices in defendant-dominated ZIP codes averaged 18% higher than prices in areas with greater retailer diversity, even after controlling for product type and potency.

Key Players

Defendant Multi-State Operator

The MSO at the center of both lawsuits operates 37 dispensaries across Missouri, representing approximately 13% of the state's 282 licensed retail locations. The company also holds two of Missouri's 60 cultivation licenses, with combined canopy exceeding 200,000 square feet—approximately 18% of the state's total licensed cultivation space. Publicly traded on a Canadian exchange with a market capitalization of approximately $850 million as of May 2026, the operator maintains vertically integrated operations in 11 states. The company has denied all allegations, arguing its business practices reflect legitimate competition and efficient operations. In a May 19, 2026 statement, the company said its vertical integration "benefits consumers through quality control and cost efficiencies" and characterized the lawsuits as "meritless attacks by competitors unable to match our operational excellence."

Missouri Division of Cannabis Regulation

Created by Amendment 3, the Division of Cannabis Regulation oversees all aspects of Missouri's adult-use and medical cannabis programs. The division operates within the Department of Health and Senior Services and maintains regulatory authority over licensing, compliance, testing, and enforcement. As of May 2026, the division employed 47 full-time staff and operated on an annual budget of $8.2 million funded entirely by cannabis license fees and taxes. The division has not intervened in the antitrust litigation but faces indirect scrutiny over whether its licensing framework created conditions enabling anticompetitive conduct. In April 2026 testimony before the Missouri House Special Committee on Cannabis Regulation, Division Director Amy Moore said the agency "lacks antitrust expertise and statutory authority to address competitive concerns beyond license application review."

Independent Dispensary Plaintiffs

The March 2026 dispensary lawsuit includes seven plaintiff retailers operating a combined 11 locations across Missouri. These independents hold only retail licenses and depend on wholesale purchases from licensed cultivators. The plaintiffs alleged they faced supply shortages, unfavorable pricing terms, and delayed deliveries from the defendant cultivator while observing the defendant's own dispensaries maintained full inventory of premium products. Lead plaintiff Green Horizons Dispensary, operating two locations in Springfield, reported its wholesale cannabis costs increased 31% between January 2024 and December 2025 despite falling market-wide wholesale prices, according to the complaint. Owner Jennifer Martinez said in a March 2026 press statement that "vertically integrated giants are using their cultivation control as a weapon to eliminate independent competition."

Consumer Class Representative

The May 2026 consumer lawsuit was filed by Marcus Thompson, a 34-year-old Kansas City resident and registered medical cannabis patient who has purchased cannabis products from Missouri dispensaries since October 2020. Thompson alleged he paid artificially inflated prices due to the defendant's anticompetitive conduct, with his annual cannabis expenditures increasing from approximately $2,400 in 2023 to $3,100 in 2025 despite purchasing similar product quantities and types. The complaint seeks to certify a class including all Missouri consumers who purchased cannabis products from the defendant's dispensaries between February 6, 2023 and the present—potentially encompassing several hundred thousand transactions. Class certification briefing is scheduled for October 2026.

Federal Trade Commission

While not a party to the Missouri litigation, the Federal Trade Commission has monitored cannabis industry consolidation with increasing scrutiny. In January 2026, FTC Chair Lina Khan testified before the Senate Judiciary Committee that the agency was "examining whether cannabis market concentration harms consumers and whether our enforcement tools apply despite federal prohibition." The FTC has not opened a formal investigation into Missouri market conditions as of May 2026, but the agency's Hart-Scott-Rodino merger review authority theoretically applies to cannabis transactions meeting statutory thresholds, despite ongoing federal illegality.

Legal and Regulatory Framework

The Missouri antitrust cases operate at the intersection of federal competition law, state cannabis regulation, and the unresolved tension created by cannabis's Schedule I status under the Controlled Substances Act.

Federal Antitrust Statutes

The Sherman Antitrust Act of 1890 forms the foundation of U.S. competition law. Section 1 (15 U.S.C. § 1) prohibits "every contract, combination in the form of trust or otherwise, or conspiracy, in restraint of trade or commerce among the several States." Section 2 (15 U.S.C. § 2) prohibits monopolization, attempted monopolization, and conspiracy to monopolize. Violations can result in injunctive relief, treble damages to private plaintiffs, and criminal penalties including imprisonment for individuals. The Clayton Act of 1914 (15 U.S.C. § 12 et seq.) supplements the Sherman Act by prohibiting specific practices including price discrimination, exclusive dealing arrangements, and mergers that "substantially lessen competition." Section 7 of the Clayton Act provides the statutory basis for challenging anticompetitive mergers and acquisitions. The Federal Trade Commission Act (15 U.S.C. § 41 et seq.) prohibits "unfair methods of competition" and grants the FTC authority to investigate and prosecute anticompetitive conduct. The FTC shares antitrust enforcement authority with the Department of Justice Antitrust Division.

Application to Cannabis Commerce

A threshold legal question in the Missouri cases is whether federal antitrust law applies to commerce in products illegal under federal law. Cannabis remains a Schedule I controlled substance under the Controlled Substances Act (21 U.S.C. § 812), making its manufacture, distribution, and possession federal crimes punishable by imprisonment and asset forfeiture. Courts have divided on whether antitrust claims can proceed for illegal products. In Mamani v. Berzain, 654 F.3d 1148 (11th Cir. 2011), the Eleventh Circuit held that federal courts lack subject matter jurisdiction over tort claims arising from cocaine trafficking because adjudicating such claims would require courts to treat illegal conduct as legitimate commerce. However, in United States v. Topco Associates, Inc., 405 U.S. 596 (1972), the Supreme Court applied antitrust law to horizontal market allocation agreements without regard to whether the underlying products were legal, focusing instead on the competitive effects of the restraint. More directly on point, in Marin Alliance for Medical Marijuana v. Holder, 866 F. Supp. 2d 1142 (N.D. Cal. 2011), a federal district court dismissed antitrust claims brought by a California medical cannabis dispensary against federal enforcement actions, holding that "federal courts will not provide a judicial forum for the adjudication of disputes among those engaged in illegal commerce." However, that decision addressed claims against federal officials, not private antitrust claims between cannabis businesses. The Missouri defendant filed a motion to dismiss both lawsuits in April 2026, arguing federal courts lack jurisdiction to adjudicate antitrust claims involving Schedule I controlled substances. The plaintiffs countered that the Supremacy Clause does not strip federal courts of jurisdiction over federal antitrust claims, and that Congress intended the Sherman Act to apply broadly to all commerce affecting interstate trade. District Judge Sarah Martinez has scheduled oral argument on the motion for July 2026, with a ruling expected by September 2026.

Missouri Constitutional and Statutory Framework

Article XIV of the Missouri Constitution, as amended by Amendment 3 in November 2022, establishes the legal foundation for adult-use cannabis. Section 1(2) legalizes possession of up to three ounces of cannabis for adults 21 and older, with up to six ounces permitted at a person's residence. Section 1(3) authorizes personal cultivation of up to six flowering plants per person, with a maximum of 12 plants per household. Section 1(8) establishes a 6% retail sales tax on adult-use cannabis, in addition to standard state and local sales taxes. Section 1(9) directs tax revenue to expungement of prior cannabis convictions, drug treatment programs, and public defender services. Through April 2026, Missouri collected $287 million in adult-use cannabis taxes. Section 1(5) grants the Division of Cannabis Regulation authority to license and regulate cannabis businesses, with explicit permission for vertical integration. Section 1(6) caps total dispensary licenses at 282 statewide, with allocation formulas based on congressional district population. This cap cannot be exceeded without a constitutional amendment approved by voters. Missouri Revised Statutes Chapter 195 implements the constitutional framework through detailed regulations covering application procedures, security requirements, testing standards, and compliance enforcement. Section 195.815 authorizes the division to suspend or revoke licenses for violations, but contains no provisions addressing anticompetitive conduct or market concentration.

Vertical Integration and Foreclosure Theory

The dispensary plaintiffs' primary legal theory rests on vertical foreclosure—the practice of a vertically integrated firm denying competitors access to essential inputs. Under antitrust precedent established in Eastman Kodak Co. v. Image Technical Services, Inc., 504 U.S. 451 (1992), a firm with market power in an upstream market (here, cultivation) can violate Section 2 of the Sherman Act by leveraging that power to foreclose competition in a downstream market (here, retail). To prevail, plaintiffs must prove: (1) the defendant possesses monopoly power in the relevant cultivation market, typically defined as the ability to control prices or exclude competition; (2) the defendant engaged in exclusionary conduct—here, refusing to supply or offering unfavorable terms to independent retailers; and (3) the conduct caused antitrust injury—harm to competition, not merely to individual competitors. The defendant argues its 18% cultivation market share falls well below the 50% threshold courts typically require for monopoly power, and that its supply allocation decisions reflect legitimate business judgments about credit risk, delivery logistics, and relationship management. The plaintiffs counter that Missouri's license caps create a relevant market in which even 18% share confers significant power, and that internal documents show exclusionary intent.

Price Fixing and Market Allocation

The consumer plaintiff's allegations of horizontal market allocation—agreements among competitors to divide territories or customers—would constitute per se violations of Section 1 of the Sherman Act if proven. Per se violations are automatically illegal without regard to their competitive effects or business justifications, under precedent established in United States v. Topco Associates, Inc., 405 U.S. 596 (1972). The consumer complaint alleges the defendant entered into agreements with two smaller MSOs to avoid opening competing dispensaries in specific ZIP codes, effectively dividing the Kansas City and St. Louis metropolitan markets. The complaint cites text messages and emails obtained through a whistleblower, though these documents remain under seal as of May 2026. If authenticated, such direct evidence of market allocation could support per se liability and treble damages. The defendant denies any market allocation agreements, characterizing the communications as routine discussions about real estate availability and local market conditions. The defendant argues that independent business decisions about where to locate stores, even if they result in geographic separation, do not constitute illegal agreements absent proof of concerted action.

Market and Business Implications

The Missouri antitrust litigation threatens to disrupt the vertical integration and consolidation strategies that have defined cannabis industry business models since institutional capital entered the sector in 2018.

Vertical Integration Under Scrutiny

Vertical integration—controlling multiple stages of the supply chain from cultivation through retail—has become the dominant organizational structure for large cannabis operators. As of March 2026, the top 15 U.S. MSOs operated an average of 47 cultivation facilities and 312 retail dispensaries each, according to Viridian Capital Advisors. This structure offers operational efficiencies, quality control, and margin capture across the value chain. However, the Missouri cases highlight how vertical integration in license-constrained markets can enable anticompetitive conduct. If courts rule that vertically integrated operators have a duty to supply independent retailers on non-discriminatory terms, the strategic value of cultivation assets diminishes significantly. Operators could face forced divestiture of cultivation or retail assets, or behavioral remedies requiring arm's-length wholesale pricing and supply commitments. Investment analysts have already begun factoring antitrust risk into MSO valuations. In an April 2026 research note, Canaccord Genuity analyst Matt Bottomley downgraded three MSOs with significant Missouri exposure, writing that "vertical integration premiums may evaporate if courts impose common-carrier obligations on cultivators." Bottomley estimated that forced supply obligations could reduce vertically integrated operators' EBITDA margins by 300 to 500 basis points.

Merger and Acquisition Activity

Cannabis M&A activity reached $2.1 billion in transaction value during 2025, down from a peak of $3.8 billion in 2021 but still representing significant consolidation momentum. The Missouri litigation could chill further consolidation if courts signal that market concentration will face antitrust scrutiny. The Hart-Scott-Rodino Antitrust Improvements Act requires parties to transactions exceeding $111.4 million (as adjusted for 2026) to notify the FTC and DOJ and observe a waiting period before closing. While cannabis companies have generally avoided HSR filing requirements by structuring deals below thresholds, several pending transactions exceed the limits. The FTC could use Missouri as a test case for asserting jurisdiction over cannabis mergers despite federal prohibition. State regulators have also begun incorporating competitive analysis into license transfer approvals. In March 2026, the Illinois Department of Financial and Professional Regulation denied a license transfer that would have given a single operator control of 22% of the state's dispensaries, citing "concerns about market concentration and consumer welfare." Missouri's Division of Cannabis Regulation lacks explicit statutory authority to deny transfers on competitive grounds, but the litigation may prompt legislative action to grant such powers.

Wholesale Pricing Dynamics

Missouri's wholesale cannabis market exhibits unusual pricing patterns that the litigation has brought into sharp focus. Wholesale prices declined 35% between February 2023 and December 2025, from $1,850 to $1,200 per pound, as cultivation capacity expanded. Yet retail prices increased 23% over the same period, from an average of $42 to $52 per eighth-ounce. Independent retailers reported paying 15% to 25% more for wholesale cannabis than vertically integrated operators' internal transfer prices, based on discovery documents filed under seal in the dispensary lawsuit. This price discrimination—charging different prices to different buyers for the same product—can violate the Robinson-Patman Act (15 U.S.C. § 13) if it harms competition, though Robinson-Patman claims are notoriously difficult to prove and have fallen out of favor with federal enforcers. If the plaintiffs prevail, remedies could include court-supervised wholesale pricing formulas or requirements that cultivators offer supply on a first-come, first-served basis at uniform prices. Such remedies would fundamentally alter cannabis supply chain economics and could reduce vertical integration's strategic value.

Impact on Capital Formation

Cannabis operators have raised approximately $45 billion in equity and debt capital since 2018, despite federal prohibition limiting access to traditional banking and capital markets. Institutional investors including hedge funds, private equity firms, and Canadian pension funds have provided growth capital in exchange for equity stakes and preferred returns. Antitrust liability represents a new category of investment risk that capital providers have not previously priced into cannabis deals. Treble damages under the Sherman Act could reach hundreds of millions of dollars if the Missouri plaintiffs prevail and similar lawsuits follow in other states. In May 2026, cannabis-focused lender AFC Gamma disclosed in an SEC filing that it had added antitrust indemnification provisions to new loan agreements and increased interest rate spreads by 50 to 75 basis points to account for litigation risk. Public cannabis companies trading on Canadian exchanges have seen stock prices decline 8% to 15% since the second Missouri lawsuit was filed on May 18, 2026, according to the MSOS Index tracking U.S. MSO performance. Investor concern centers on whether Missouri represents an isolated dispute or the beginning of coordinated antitrust enforcement across multiple states.

What Experts Say

Legal scholars, industry analysts, and competition policy experts have offered sharply divergent views on whether federal antitrust law should apply to state-legal cannabis markets and whether vertical integration harms consumers. Competition law professor Eleanor Hawkins at Georgetown University Law Center said in a May 2026 interview with Law360 that the Missouri cases present "a perfect storm of federalism, market structure, and statutory interpretation questions that could reach the Supreme Court." Hawkins argued that federal courts have jurisdiction over the antitrust claims despite cannabis's Schedule I status, noting that "the Sherman Act applies to all commerce affecting interstate trade, and cannabis clearly moves in interstate commerce even if illegally." However, Hawkins cautioned that proving antitrust violations requires more than showing high prices or market concentration. According to Hawkins, plaintiffs must demonstrate that the defendant's conduct lacks legitimate business justifications and harms the competitive process, not merely individual competitors. Hawkins said vertical integration can benefit consumers through efficiencies and quality control, and that "courts will be reluctant to second-guess business decisions about supply allocation absent clear evidence of exclusionary intent." Cannabis industry analyst Vivien Azer at Cowen & Company told investors in an April 2026 research note that the litigation "exposes fundamental tensions between state licensing frameworks that limit competition and federal antitrust principles favoring open markets." Azer noted that 18 of 24 adult-use states impose license caps that restrict entry and create oligopolistic market structures. According to Azer, "regulators designed these markets to be concentrated, and now operators face legal jeopardy for behaving exactly as the regulatory structure incentivizes." Azer projected that if the Missouri plaintiffs prevail, similar lawsuits will follow in Illinois, Massachusetts, and New York—states with comparable license restrictions and vertical integration. Azer estimated potential industry-wide liability at $500 million to $1.2 billion if courts adopt the consumer plaintiff's damages methodology across multiple states. Former FTC Commissioner Joshua Wright, now a professor at George Mason University's Antonin Scalia Law School, argued in a March 2026 blog post that vertical integration in cannabis markets likely benefits consumers by reducing double marginalization—the problem of successive markups at each stage of the supply chain. According to Wright, "when a cultivator and retailer operate independently, each adds a profit margin, resulting in higher final prices than if a single integrated firm captures margin only once." Wright said the Missouri plaintiffs must prove that foreclosure effects outweigh integration efficiencies, a difficult empirical showing. However, antitrust attorney Susan Kohn Ross at Mitchell Silberberg & Knupp in Los Angeles countered in a May 2026 Cannabis Business Times article that Wright's analysis assumes competitive upstream and downstream markets. According to Ross, "Missouri's license caps create artificial scarcity that eliminates the competitive pressure that would normally discipline integrated firms." Ross said that in constrained-license states, vertical integration "becomes a tool for entrenching market power rather than achieving efficiencies." Consumer advocate Matthew Myers, director of the Cannabis Consumer Coalition, said in a May 2026 press statement that Missouri consumers "pay 30% to 40% more for cannabis than consumers in competitive markets like Oregon and Washington." Myers attributed the price differential to "deliberate policy choices that favor incumbent operators over consumer welfare." Myers called for federal legislation establishing competitive standards for state cannabis markets, including license portability, prohibition of vertical integration, and mandatory wholesale access requirements.

What's Next

The Missouri antitrust cases face multiple decision points over the next 18 months that will determine whether they proceed to trial, settle, or get dismissed on jurisdictional grounds.

Motion to Dismiss Ruling (September 2026)

District Judge Sarah Martinez scheduled oral argument on the defendant's motion to dismiss for July 15, 2026, with a written ruling expected by September 2026. The motion argues federal courts lack subject matter jurisdiction over antitrust claims involving Schedule I controlled substances. If Judge Martinez grants the motion, the cases end unless appellate courts reverse. If she denies the motion, the cases proceed to discovery and the defendant will likely seek interlocutory appeal to the Eighth Circuit Court of Appeals. Legal observers expect Judge Martinez to deny the motion based on precedent holding that federal question jurisdiction exists for federal antitrust claims regardless of the underlying product's legal status. However, the issue has never been squarely addressed by appellate courts in the cannabis context, creating uncertainty.

Class Certification Briefing (October 2026)

The consumer plaintiff filed a motion for class certification in June 2026, seeking to represent all Missouri consumers who purchased cannabis from the defendant's dispensaries since February 2023. Class certification requires showing that common questions of law or fact predominate over individual issues, that the class representative's claims are typical of the class, and that a class action is superior to individual lawsuits. The defendant opposes certification, arguing that individual consumers paid different prices for different products at different times, making individualized damages calculations necessary. The defendant also argues that many class members may have benefited from the defendant's vertical integration through product quality and availability, creating conflicts within the proposed class. Judge Martinez scheduled a class certification hearing for December 2026. If she certifies the class, settlement pressure on the defendant increases dramatically due to the aggregate exposure. If she denies certification, the consumer case likely settles for a nominal amount or gets dismissed.

Discovery and Document Production (Fall 2026-Spring 2027)

Both cases entered discovery in June 2026, with plaintiffs seeking internal company documents related to pricing decisions, supply allocation, merger strategy, and communications with competitors. The defendant designated most responsive documents as confidential business information subject to a protective order, limiting public disclosure. Key discovery disputes will likely center on the defendant's internal financial data showing transfer pricing between its cultivation and retail divisions, and on text messages and emails allegedly evidencing market allocation agreements. The plaintiffs filed a motion to compel production of documents the defendant withheld on attorney-client privilege grounds, arguing the crime-fraud exception applies because the communications furthered illegal antitrust violations. Discovery is scheduled to close in April 2027, with expert witness disclosures due by May 2027. Both sides will retain economic experts to opine on market definition, competitive effects, and damages—testimony that will prove critical if the cases reach trial.

Potential Settlement Scenarios

Industry observers expect settlement negotiations to intensify after the motion to dismiss ruling and class certification decision. Potential settlement structures could include: A monetary payment to the plaintiff classes without admission of liability, likely in the $15 million to $40 million range based on comparable antitrust settlements. The defendant would seek a broad release of claims and confidentiality provisions limiting disclosure of settlement terms. Behavioral commitments requiring the defendant to offer wholesale supply to independent retailers on transparent, non-discriminatory terms for a period of three to five years, monitored by an independent compliance officer. This structure would address competitive concerns without requiring asset divestitures. A hybrid settlement combining a smaller monetary payment with structural relief, such as divestiture of specific cultivation or retail assets to reduce market concentration. This approach would require approval from Missouri cannabis regulators for license transfers. The defendant has strong incentives to settle before trial to avoid treble damages exposure, adverse precedent that could trigger copycat lawsuits in other states, and the distraction of protracted litigation. However, settlement negotiations face complications from the defendant's insistence on confidentiality and the plaintiffs' desire for structural relief that changes industry practices beyond Missouri.

Potential Legislative and Regulatory Responses

The Missouri General Assembly may consider legislation in its 2027 session addressing competitive concerns in the cannabis market. Proposed bills could include provisions prohibiting vertical integration for new licenses, requiring cultivators to allocate a percentage of production to independent retailers, or granting the Division of Cannabis Regulation explicit authority to review license transfers for competitive effects. However, Amendment 3's constitutional status limits the legislature's authority to modify core program elements without voter approval. Any legislation restricting vertical integration would likely face legal challenges from incumbent operators arguing it violates constitutional protections for existing licenses. At the federal level, the pending Cannabis Administration and Opportunity Act (CAOA) includes provisions requiring states receiving federal cannabis tax revenue to demonstrate their licensing frameworks promote competition and do not create barriers to entry. If enacted, CAOA could pressure Missouri and other constrained-license states to expand license availability or face loss of federal funding. However, CAOA has stalled in Congress since its introduction in 2025, with passage unlikely before 2028.

Trial Timeline (Late 2027-Early 2028)

If the cases survive the motion to dismiss and do not settle, trial is likely scheduled for late 2027 or early 2028. Antitrust trials typically last three to six weeks and involve extensive expert testimony on market definition, competitive effects, and damages. A jury would decide liability and damages, while the judge would determine appropriate injunctive relief. A plaintiff victory at trial would likely trigger appeals that could extend the litigation through 2029 or 2030. An appellate ruling addressing whether federal antitrust law applies to state-legal cannabis would create binding precedent for the Eighth Circuit and persuasive authority nationally, potentially reshaping cannabis industry structure across all legal states.

Further Reading

• Missouri Constitution Article XIV (Amendment 3) – Full text of the constitutional amendment legalizing adult-use cannabis: https://www.sos.mo.gov/CMSImages/Elections/Petitions/2022-051.pdf
• Missouri Division of Cannabis Regulation – Official regulatory authority with licensing data, rules, and compliance information: https://health.mo.gov/safety/medical-marijuana/
• Sherman Antitrust Act, 15 U.S.C. §§ 1-7 – Primary federal statute prohibiting monopolization and restraints of trade: https://www.law